BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program

Bulletin Express05-22

Brii Biosciences Limited (BRII-B) has disclosed that its wholly-owned subsidiary, Brii Biosciences Offshore Limited, has filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. against U.S.-based Vir Biotechnology, Inc. The action alleges breaches of both their 2018 Collaboration, Option and License Agreement and a subsequent Sixth Letter Agreement signed on 19 December 2024, which shifted drug-product formulation manufacture for the elebsiran program from Vir to Brii.

The collaboration, first executed on 23 May 2018, grants each party options for exclusive licences to develop and commercialise the other’s product candidates. Brii exercised its option on 12 June 2020 for elebsiran, a small-interfering RNA candidate targeting hepatitis B virus.

According to the 22 May 2026 announcement, the arbitration is in its early stages and no resolution has been reached. Brii states that continued delays resulting from the dispute have created material uncertainty for the elebsiran program; the company will not commit resources to a Phase 3 clinical study of any elebsiran-containing combination therapy until the claims are settled.

Management will assess ongoing developments and update shareholders as required under Hong Kong listing regulations. Investors are advised to exercise caution when dealing in BRII-B shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125921226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125921226","market":"hk","top_or_hot":-1,"title":"BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program","media":"Bulletin Express","content":"<p>Brii Biosciences Limited (BRII-B) has disclosed that its wholly-owned subsidiary, Brii Biosciences Offshore Limited, has filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. against U.S.-based Vir Biotechnology, Inc. The action alleges breaches of both their 2018 Collaboration, Option and License Agreement and a subsequent Sixth Letter Agreement signed on 19 December 2024, which shifted drug-product formulation manufacture for the elebsiran program from Vir to Brii.</p>\n<p>The collaboration, first executed on 23 May 2018, grants each party options for exclusive licences to develop and commercialise the other’s product candidates. Brii exercised its option on 12 June 2020 for elebsiran, a small-interfering RNA candidate targeting hepatitis B virus.</p>\n<p>According to the 22 May 2026 announcement, the arbitration is in its early stages and no resolution has been reached. Brii states that continued delays resulting from the dispute have created material uncertainty for the elebsiran program; the company will not commit resources to a Phase 3 clinical study of any elebsiran-containing combination therapy until the claims are settled.</p>\n<p>Management will assess ongoing developments and update shareholders as required under Hong Kong listing regulations. Investors are advised to exercise caution when dealing in BRII-B shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-22 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Brii Biosciences Limited (BRII-B) has disclosed that its wholly-owned subsidiary, Brii Biosciences Offshore Limited, has filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. against U.S.-based Vir Biotechnology, Inc. The action alleges breaches of both their 2018 Collaboration, Option and License Agreement and a subsequent Sixth Letter Agreement signed on 19 December 2024, which shifted drug-product formulation manufacture for the elebsiran program from Vir to Brii.</p>\n<p>The collaboration, first executed on 23 May 2018, grants each party options for exclusive licences to develop and commercialise the other’s product candidates. Brii exercised its option on 12 June 2020 for elebsiran, a small-interfering RNA candidate targeting hepatitis B virus.</p>\n<p>According to the 22 May 2026 announcement, the arbitration is in its early stages and no resolution has been reached. Brii states that continued delays resulting from the dispute have created material uncertainty for the elebsiran program; the company will not commit resources to a Phase 3 clinical study of any elebsiran-containing combination therapy until the claims are settled.</p>\n<p>Management will assess ongoing developments and update shareholders as required under Hong Kong listing regulations. Investors are advised to exercise caution when dealing in BRII-B shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"","article_id":"1125921226","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125921226","pubTimestamp":1779441827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Brii Biosciences Limited (BRII-B) has disclosed that its wholly-owned subsidiary, Brii Biosciences Offshore Limited, has filed a demand for arbitration with Judicial Arbitration and Mediation...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02137":"腾盛博药-B"},"translate_title":"BRII-B对Vir Biotechnology提起仲裁，给Elebsiran乙肝项目带来不确定性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"Brii Biosciences Limited (BRII-B) has disclosed that its wholly-owned subsidiary, Brii Biosciences Offshore Limited, has filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. against U.S.-based Vir Biotechnology, Inc. The action alleges breaches of both their 2018 Collaboration, Option and License Agreement and a subsequent Sixth Letter Agreement signed on 19 December 2024, which shifted drug-product formulation manufacture for the elebsiran program from Vir to Brii.\nThe collaboration, first executed on 23 May 2018, grants each party options for exclusive licences to develop and commercialise the other’s product candidates. Brii exercised its option on 12 June 2020 for elebsiran, a small-interfering RNA candidate targeting hepatitis B virus.\nAccording to the 22 May 2026 announcement, the arbitration is in its early stages and no resolution has been reached. Brii states that continued delays resulting from the dispute have created material uncertainty for the elebsiran program; the company will not commit resources to a Phase 3 clinical study of any elebsiran-containing combination therapy until the claims are settled.\nManagement will assess ongoing developments and update shareholders as required under Hong Kong listing regulations. Investors are advised to exercise caution when dealing in BRII-B shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125921226","isCrawlerRequest":true}